Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-149-7_10

Chapter 10: Regulatory, Ethical and Current Status (Clinical trials & Patents) in Nano-Brain Drug Delivery

Sonal Sharma[1], Himanshi[2], Jyoti Jwala[3], Khusbu[3], Kushal Sharma[4], Sudipa Debnath[5], Dilip Agrawal[1], Rishabh Gupta[6], Binita Ghosh[1]*

[1]*Mahatma Gandhi College of Pharmaceutical Sciences, ISI-15 A, RIICO Institutional area, Sitapura, Jaipur-302022, India.*
[2]*Department of Pharmacy Practice, Rama University, Mandhana, Kanpur, India.*
[3]*Yashodha Super Speciality Hospital, Kaushambi, Ghaziabad, India.*
[4]*Dr. Kedarnath Modi Institute of Pharmaceutical Education and Research, India.*
[5]*Fortis Hospital, Jaipur, Rajasthan, India.*
[6]*Department of Pharmacy, Jagannath University, Jaipur, Rajasthan, India.*
Corresponding Author
Dr. Binita Ghosh
Email: *binitaghosh66746@gmail.com*

Abstract

Nano-brain drug delivery systems provide improved precision and effectiveness in targeting the brain; however, they also bring forth significant issues related to regulation, ethics, clinical validation, and intellectual property. The emergence of nanotechnology in neuroscience has transformed drug delivery methods, especially in the treatment of intricate neurodegenerative diseases such as Alzheimer's disease (AD). This chapter seeks to deliver a thorough overview of the existing regulatory frameworks, ethical considerations, and the changing landscape of clinical trials and patents associated with nano-brain drug delivery, as well as future directions in AD. The database has thoroughly explained and identified current regulatory policies from major agencies (FDA, EMA, and CDSCO), ethical guidelines, clinical trial registries, and patent databases. It aims to highlight global trends and inconsistencies observed over recent decades. Ethical dilemmas such as patient autonomy, neuroprivacy, and long-term safety are inadequately addressed in the current frameworks. While the quantity of clinical trials focused on nano-brain drug delivery is growing, they are still restricted in both quantity and breadth, highlighting translational obstacles. Patent activity in this field is on the rise, mainly driven by a limited number of academic and industry collaborators, yet it faces challenges due to the intricacy and novelty of nano-drug formulations. Nano-brain drug delivery holds considerable promise for

Alzheimer's disease, and enhanced transparency, interdisciplinary cooperation, and proactive policy changes are essential to bridge the divide between innovation and patient accessibility.

Keywords: *Nanomedicine, Alzheimer's disease, treatment, nanotechnology, clinical trials.*

1. Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by memory impairment, cognitive deterioration, and behavioral issues, making it one of the most pressing public health challenges worldwide. Although significant research has been conducted, existing pharmacological treatments provide only symptomatic relief and do not significantly alter the course of the disease. A significant challenge in effective treatment is the blood-brain barrier (BBB), a highly selective physiological barrier that limits the passage of most therapeutic agents into the central nervous system (CNS). Therefore, there is an urgent need for innovative delivery methods that can bypass this barrier and enable targeted delivery of therapeutic agents to brain tissues [1-2].

Nonetheless, the swift advancement of nanotechnology in neuroscience presents numerous translational obstacles, particularly in the regulatory sphere. Current regulatory systems, primarily designed for traditional pharmaceuticals, frequently prove inadequate when addressing nanomedicines due to their intricate physicochemical characteristics. Factors such as particle size, surface charge, shape, and bio-distribution play a crucial role in determining the therapeutic efficacy and safety of nanoformulations, which calls for tailored evaluation methods. Regulatory agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO) in India are slowly evolving, yet discrepancies remain in the classification, evaluation, and approval processes for nanomedicines across various regions. This absence of standardization poses challenges for the global development, approval, and distribution of nano-based treatments for CNS disorders [3-5].

Intellectual property rights and patent protections are essential elements in the development of nano-brain therapeutics. The complexity of nanocarrier systems, which frequently incorporate multilayered advancements in materials science, drug formulation,

and targeting mechanisms, makes the patenting process more challenging. Conflicting claims and uncertainties in establishing novelty can result in legal conflicts and impede collaborative research [4]. Concerns regarding monopolisation and the affordability of sophisticated nanotherapeutics are also raised by the fact that a small number of multinational corporations dominate the patent filing market. Since the prevalence of Alzheimer's disease is rising in low- and middle-income nations, the high price of patented nanodrugs may significantly restrict access [5].

The field of Alzheimer's clinical trials including nano-brain medication delivery is still in its infancy. Although a number of preclinical investigations have shown encouraging results in animal models, the quantity and extent of human trials are still restricted. The main goals of early-phase clinical trials are to assess innovative nanoformulations' safety, tolerability, and first efficacy. But there are many obstacles in the way of moving from Phase I to extensive Phase III trials, such as scalability in manufacturing, obtaining regulatory permissions, finding individuals with cognitive impairments, and standardising endpoints [6]. Furthermore, meta-analytical assessments and regulatory benchmarking are hampered by variations in trial design and outcome measures. Given these complex issues, it is clear that ethical and regulatory considerations are essential to the effective creation and uptake of nano-brain medication delivery devices rather than being incidental issues. It is essential to use a translational approach that combines sound knowledge, flexible legislation, and proactive ethical governance. Collaborative efforts involving academia, industry, regulators, ethicists, clinicians, and patient advocacy groups are essential to building trust and ensuring that nano-brain technologies are developed responsibly and delivered equitably. The road ahead must include adaptive policy frameworks, investment in regulatory science, harmonization of international guidelines, and the inclusion of patient perspectives in decision-making processes [6-9].

Nanotechnology has emerged as a revolutionary approach as novel solutions for brain drug delivery. Nano-brain drug delivery systems utilize nanocarriers such as liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, micelles, and more recently, biological nanocarriers. These technologies offer improved medication stability, controlled release, and targeted delivery. Nanocarriers can penetrate the

blood-brain barrier and gather in particular brain areas impacted by AD by means of surface functionalisation and receptor-mediated transport [10]. Furthermore, theranostic systems-multifunctional nanoplatforms that combine therapeutic and diagnostic capabilities-are being created to enable real-time tracking and individualised treatment plans. These developments have the potential to revolutionise the therapeutic treatment of AD by increasing bioavailability, reducing systemic toxicity, and making disease-modifying therapies possible [11].

Nano brain delivery

These complex issues may be beyond the scope of current bioethical guidelines, which are frequently based on broad biological research concepts. A specific neuroethical framework that is adapted to the special connections between brain-targeted therapies, cognitive disability, and nanotechnology is becoming more and more demanded. This involves creating ethical review processes that put an emphasis on openness, protect patient dignity, and guarantee deep interaction with patient communities and carers. As a proactive tactic, ethical-by-design methodologies-where moral protections are incorporated into the technological development process-are increasingly becoming more popular [12-15].



Figure 10.1. Illustration of the nanocarriers' mode of transport to the brain in the treatment of AD

This chapter presents a thorough analysis of the regulatory environment, ethical dilemmas, ongoing clinical trials, and intellectual property concerns (patents) that are influencing the future of nano-brain drug delivery for AD. It identifies significant gaps and offers practical recommendations designed to promote the safe, ethical, and effective transition of this innovative technology from laboratory research to practical clinical applications.

2. Regulatory Frameworks For Nano-Brain Drug Delivery

The rise of nanotechnology in the treatment of Alzheimer's disease has necessitated the evolution of regulatory frameworks that govern the development, approval, and oversight of nano-brain drug delivery systems (**Table 10.1**). Globally, regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO) have begun to respond to the unique demands of these advanced therapeutics. The FDA evaluates nanomedicines on a product-specific basis, often under the same frameworks used for conventional drugs, biologics, or devices, depending on the product's mechanism of action. Its Nanotechnology Task Force and associated guidance documents stress the need for robust characterization of nanomaterials, including aspects such as particle size, surface chemistry, and stability [14-17].

Meanwhile, the EMA in Europe, through its Nanomedicines Working Group, has issued reflection papers and scientific recommendations on the quality, safety, and efficacy standards for nanotechnology-based products. Though the EMA has not created a new legal category for nanomedicines, it emphasizes early scientific advice and centralized approval pathways for novel formulation [18-19]. Similarly, India's CDSCO, in collaboration with the Indian Council of Medical Research (ICMR), has drafted regulatory guidelines for nanopharmaceuticals, which underscore quality control, biocompatibility, and nano-specific risk assessment. Other regulatory bodies, such as Japan's PMDA and China's NMPA, are also building their regulatory capacities. Despite these efforts, a lack of harmonization in definitions, evaluation metrics, and safety thresholds remains a significant bottleneck in the global advancement of nano-brain drug delivery [20].

2.1. FDA

The development of nanotechnology-based drug delivery systems for brain disorders requires strict adherence to evolving regulatory guidelines to ensure safety, efficacy, and quality. Regulatory bodies such as the U.S. FDA, EMA, and WHO emphasize detailed physicochemical characterization of nanocarriers, including particle size, surface charge, morphology, drug loading, and release profiles. Specific attention is given to their ability to cross the blood-brain barrier (BBB), with mandates for biodistribution and targeting validation through in vitro and in vivo models [21].

Toxicological evaluations must address neurotoxicity, immunogenicity, and potential long-term accumulation in neural tissues, guided by standards from organizations like OECD and ISO. Clinical translation demands compliance with Good Manufacturing Practices (GMP), risk-benefit assessments, and neuropharmacokinetic studies, as outlined in FDA and EMA guidance documents. Ethical considerations are critical, particularly regarding informed consent and the use of nanomedicines in vulnerable populations such as patients with neurodegenerative diseases. In order to monitor long-term safety and uncommon side effects, agencies are promoting the adoption of nano-specific pharmacovigilance techniques, which is another crucial criterion for post-marketing surveillance. When taken as a whole, these recommendations offer a methodical framework for safely advancing nano-brain therapies from study to clinical use [21-22].

2.2. EMA

Within the European Union, the European Medicines Agency is crucial in regulating nano-based brain medication delivery systems, making sure that these goods fulfil strict safety, effectiveness, and quality requirements prior to being approved. The EMA uses a product-specific scientific evaluation procedure for nanomedicines that target the central nervous system (CNS), such as those for Parkinson's or AD. This process frequently calls for long-term toxicity profiles, biodistribution data, and sophisticated nanocarrier characterisation. The EU's regulatory structure incorporates ethical oversight, which requires strict adherence to Good Clinical Practice (GCP), patient

safety monitoring, and informed consent [23]. The EMA promotes early scientific guidance for innovators in the field of nanotechnology, aiding in the seamless transition from preclinical discoveries to clinical trials. Recent trends indicate a rise in active clinical trials involving liposomal, polymeric, and exosome-based formulations aimed at the brain, as well as a steady growth in European patents related to nanoparticle designs, ligand-functionalization techniques, and strategies for penetrating the BBB [23-25].

2.3. CDSCO

In India, the CDSCO serves as the highest regulatory authority responsible for the approval and supervision of nano-enabled brain drug delivery systems. Following the New Drugs and Clinical Trials Rules (2019) and the Medical Devices Rules, nano-formulations are subjected to a thorough evaluation of their physicochemical properties, *in vivo* safety information, and CNS-targeting effectiveness prior to advancing to human trials. Ethical compliance is ensured through Institutional Ethics Committees (IECs) and adherence to ICMR guidelines, particularly for studies involving vulnerable populations such as neurodegenerative disease patients. The CDSCO also collaborates with the Department of Biotechnology and the Nanotechnology Mission to streamline translational research into viable therapeutics [26]. Presently, India has a growing patent landscape in nano-based CNS drug delivery, especially in polymeric nanoparticles, dendrimer conjugates, and herbal bioactives like Ginkgo biloba and Gastrodia elata for Parkinson's and AD, with several early-phase clinical trials registered in the Clinical Trials Registry–India (CTRI) [27].

2.4. Others

One of the central regulatory issues in nanomedicine development lies in the classification and approval pathways of these products. Because nanotherapeutics often span multiple categories-drug, device, and biologic-the choice of regulatory pathway depends largely on their primary mode of action. In the U.S., the FDA's Office of Combination Products determines whether a product will be reviewed as a drug, biologic, or device, which subsequently dictates preclinical and clinical data requirements [27].

In Europe, the centralized marketing authorization procedure enables nanomedicines to be evaluated by the EMA's Committee for Medicinal Products for Human Use (CHMP), while also incorporating opinions from nanomedicine experts. India's CDSCO evaluates nanopharmaceuticals under its New Drugs and Clinical Trials Rules (2019), with an emphasis on nano-specific safety and manufacturing data. Across all these regions, developers must demonstrate not only pharmacological effectiveness but also nanoparticle-specific behavior, including cellular uptake, distribution profiles, and in vivo degradation patterns. Variations in classification arise because some nanoformulations may alter a previously approved drug's pharmacokinetics, requiring full reassessment, while others may qualify for abbreviated pathways depending on prior data. Furthermore, no unified global definition of nanomedicine exists-some agencies adhere to the 1–100 nm particle size range, while others consider functionality and interaction with biological systems, making international submissions complex [28]. When it comes to brain-targeted therapies, the central nervous system (CNS) introduces an additional layer of regulatory complexity**.** The blood-brain barrier (BBB) limits the passage of most therapeutics, and nanocarriers must be carefully evaluated for their ability to cross this barrier without causing neurotoxicity. However, conventional preclinical models are insufficient to fully replicate the intricacies of the human BBB or predict long-term safety outcomes [29].

Regulatory agencies are increasingly requesting advanced biodistribution data, especially involving brain-specific tissue uptake and retention times. Moreover, nanocarriers designed for AD often involve surface modifications, ligand attachments, or encapsulated bioactive molecules, which can alter their biological behavior unpredictably [30]. Regulatory authorities are concerned about off-target effects, immune activation, or unintended interference with neurotransmitter signaling. Manufacturing consistency is also critical—minor variations in size, shape, or surface chemistry can lead to batch-to-batch variability, which impacts both efficacy and safety. Thus, regulators require detailed protocols for nanoparticle synthesis, characterization, and quality control using high-resolution analytical tools such as dynamic light scattering, transmission electron microscopy, and zeta potential analysis. Without such

precision, it becomes difficult to approve or reproduce nanoformulations, especially those designed to act within the brain [31-32].

Table 10.1: Regulatory Frameworks for Nano-Brain Drug Delivery in AD [33-35]

Aspect	Description
Global Regulatory Bodies	FDA (USA): Evaluates nanomedicine under existing frameworks (drugs/biologics/devices); relies on product-specific reviews. EMA (Europe): Uses centralized approval via CHMP; offers early scientific advice; has Nanomedicines Working Group. CDSCO (India): Operates under New Drugs and Clinical Trials Rules (2019); emphasizes biocompatibility and nano-specific safety. Others: PMDA (Japan), NMPA (China) are also developing nano-drug regulatory pathways.
Nanomaterial Characterization Requirements	Particle size, surface chemistry, morphology, stability; uses tools like TEM, DLS, zeta potential analysis. Batch-to-batch consistency is critical due to sensitivity of nanoformulations.
Classification & Approval Pathways	FDA: Classification decided by the Office of Combination Products. EMA: Uses centralized procedure with nanomedicine experts. CDSCO: Full dossier submission; some pathways influenced by prior data. Challenge: Lack of global harmonization; particle size definitions vary (e.g., 1–100 nm or functionality-based).
CNS-Specific Regulatory Considerations	Blood-brain barrier penetration must be proven using biodistribution and brain tissue uptake data. Evaluation of neurotoxicity, immune response, neurotransmitter interaction is essential. Surface-modified nanocarriers pose additional risk for off-target effects.
Manufacturing and Quality Control	Nanoparticles must be reproducible across batches; quality parameters include: - Size, shape, charge - Drug loading efficiency - Release kinetics High-resolution methods (e.g., DLS, TEM) are mandatory.
Risk-Benefit Assessment	Must include nanoparticle-specific toxicity and accumulation risks in the brain. Risk-benefit profiles consider: - Neuroinflammation - Synaptic toxicity - Glial activation - Long-term safety
Preclinical Requirements	Standardized ADME and toxicokinetic studies tailored for nanocarriers.

	Neurobehavioral studies and CNS-targeted toxicity required. Data must be GLP-compliant. Human-relevant models (e.g., brain organoids, BBB-on-chip) are gaining traction.
Challenges in Global Harmonization	Inconsistent definitions (size vs. functionality), regulatory expectations, and evaluation metrics. Complexity increases for international trials and multi-region submissions.
Emerging Trends in Regulatory Science	Adoption of AI tools for predictive modeling. Advanced in vitro testing platforms. Calls for international collaboration to align CNS nanomedicine regulatory standards.
Final Outlook	Regulatory frameworks must be adaptable, CNS-specific, and innovation-friendly. Balanced oversight ensures both patient safety and progress in Alzheimer's nanomedicine.

In conclusion, while nano-brain drug delivery systems hold transformative potential for managing AD, they introduce multifaceted challenges that require regulatory systems to evolve in both scope and sophistication. Differences in classification, regional requirements, evaluation methods, and safety concerns have created a fragmented global regulatory environment [36]. Bridging these gaps will require international collaboration, the development of CNS-specific regulatory tools, and the integration of emerging technologies such as AI-based predictive modeling and advanced *in vitro* testing. Ultimately, a balanced and adaptive regulatory framework-one that safeguards patient safety while fostering innovation-will be essential to translate nanotechnology from promising research to clinical reality in AD therapeutics [37].

3. Ethical Considerations In Nano-Brain Therapeutics

The integration of nanotechnology into therapeutics targeting the human brain presents not only scientific and regulatory challenges but also profound ethical questions. In contrast to traditional therapies, nano-brain drug delivery systems function at the molecular level and can engage with neural tissue in manners that might influence cognition, memory, behavior, and consciousness. These innovations offer the potential for accurate and focused treatment of serious ailments like AD; however, their use necessitates thorough ethical scrutiny.

Interventions at this level raise ethical questions of autonomy, long-term effects, informed permission, and moral responsibility because the brain is the site of human

identity and agency, making it ethically different from other organs. Ethical issues become even more complex in the context of AD, when patients frequently endure progressive cognitive deterioration. This calls for interdisciplinary oversight and context-sensitive decision-making. Nanotechnology's ethical effects on the human brain are intricate and multifaceted. The main concern is the possibility of unforeseen outcomes when manipulating brain networks using carriers enabled by nanotechnology. Although nanoparticles can directly deliver therapeutic compounds to sick tissues by crossing the blood-brain barrier, little is known about how they interact with neurones and glial cells. Unlike other organs, the brain governs not only physical functions but also consciousness and personality [38-39].

Therefore, altering its chemistry or structure-intentionally or otherwise—raises concerns about changes in cognition, mood, or behavior. For instance, if a nanocarrier modulates neurotransmitter activity or interferes with synaptic signaling, it could inadvertently alter the patient's personality or emotional state. These outcomes, even if rare, have moral implications that go beyond standard clinical risk-benefit assessments. Furthermore, ethical concerns are heightened when dealing with irreversible or long-acting formulations, which may have prolonged effects even after a single administration. The ethical debate also touches on human enhancement: while the intent is therapeutic, the same nano-brain platforms could theoretically be used for cognitive enhancement in the future, raising issues of fairness, identity, and social justice.Informed consent and patient autonomy are fundamental pillars of medical ethics, but they are significantly complicated in the case of nano-brain therapeutics for Alzheimer’s disease [40-41]**.**

Informed consent relies on a patient’s cognitive ability to understand the nature of the intervention, the associated risks, and the alternatives available. However, Alzheimer’s patients often experience impaired decision-making capacity due to memory loss, confusion, and declining judgment. In early stages of the disease, patients may still possess partial capacity, leading to ambiguity about the sufficiency of their consent. In later stages, consent must be obtained through legal guardians or healthcare proxies,

raising questions about surrogate decision-making and the extent to which it aligns with the patient's values and preferences [42].

Moreover, the technical complexity of nanomedicine makes it difficult for even healthy individuals to fully comprehend. Describing the behavior of nanoparticles, their long-term biodistribution, and the potential for unintended neural effects in a manner that facilitates informed consent presents a significant challenge. This scenario necessitates customized communication strategies, the engagement of ethics consultants, and possibly a reevaluation of conventional consent frameworks to better suit innovative and intricate neurotechnologies. Critical ethical concerns in the realm of nano-brain drug delivery include long-term safety, neurotoxicity, and data privacy. Although preclinical research frequently indicates that numerous nanocarriers are biocompatible, information regarding their long-term impacts on human subjects is still limited. Given the brain's heightened sensitivity and restricted regenerative ability, even slight unintended effects could lead to severe repercussions [43-45].

For example, ongoing inflammation, the buildup of nanoparticles, or disruption of neuronal circuits may lead to cognitive decline, mood disorders, or motor dysfunction. The ethical use of these technologies requires strict, long-term monitoring protocols and the establishment of ethical guidelines to decide when and how to take action if long-term effects arise. Additionally, certain nano-systems are engineered to track biological signals or facilitate drug delivery in reaction to physiological signals. These functions produce sensitive neurological data that must be securely stored and managed in an ethical manner. The emerging field of neuroethics has begun to address these concerns, advocating for standards that recognize the uniquely personal nature of brain data and calling for stricter safeguards than those applied to other types of medical data [46].

The development and application of ethical guidelines and oversight mechanisms are crucial to ensuring responsible progress in nano-brain therapeutics**.** Existing ethical review boards and institutional review committees are often structured around conventional biomedical models and may lack the expertise needed to evaluate cutting-edge nanotechnologies. The interdisciplinary nature of nano-brain delivery-combining neuroscience, nanotechnology, clinical pharmacology, and bioengineering-

requires ethical oversight bodies to evolve accordingly. Inclusion of ethicists, neuroscientists, patient advocates, and data privacy experts on review panels is essential. Some international organizations, such as UNESCO and the Council for International Organizations of Medical Sciences (CIOMS), have begun to explore guidelines for emerging technologies in the life sciences, but these are often general in nature [47-48]. The development of specific guidelines for nano-brain therapeutics must consider not only safety and efficacy but also dignity, justice, and transparency. Oversight mechanisms should include continuous ethical review throughout the research and clinical trial phases-not just at the beginning-and should allow for adaptive management if new risks or social concerns arise during implementation [49-50].

Furthermore, the principles of equity and justice should be integral to the ethical assessment of nano-brain interventions. AD has a disproportionate impact on older populations, many of whom may face socioeconomic challenges or have restricted access to specialized medical care. If nano-brain therapies are costly, patented, or controlled by a limited number of companies, they could worsen the existing inequalities in access to neurological treatment. It is essential to create ethical distribution frameworks to guarantee that these innovative therapies are not solely accessible to the affluent or those residing in developed nations. Global justice mandates that low- and middle-income countries also gain access to reasonably price nano-based therapies, and that international partnerships emphasize shared advantages, capacity enhancement, and fair knowledge sharing. Lastly, public perception and trust in nanomedicine also carry ethical weight [51].

Misunderstanding or misinformation about nanotechnology-particularly when used in the brain-could lead to fear, stigma, or resistance among patients and caregivers. Ethical implementation strategies must therefore include public engagement, education campaigns, and participatory decision-making processes. Involving patients, families, and community stakeholders in discussions about benefits, risks, and ethical safeguards can foster trust and contribute to socially responsible innovation. The ethical landscape of nano-brain drug delivery is inherently complex, shaped by the interplay between novel technologies and the sensitive, high-stakes of brain health. In Alzheimer's disease, where vulnerability and cognitive decline are central, ethical safeguards must be even

more robust and adaptive. From informed consent challenges and long-term safety concerns to issues of privacy, justice, and public trust, each dimension requires proactive ethical governance. As the field progresses, it is imperative that developers, clinicians, regulators, and ethicists work together to ensure that the pursuit of therapeutic innovation does not compromise human dignity, autonomy, or equity. A dedicated, interdisciplinary ethical framework tailored to nano-brain therapeutics is no longer optional-it is essential [52].

Table 10.2: Ethical Considerations in Nano-Brain Therapeutics (with a focus on AD) [50-53]

Ethical Domain	Key Considerations
Human Brain as a Unique Ethical Entity	- Brain governs cognition, behavior, identity, and consciousness - Nano-interventions may unintentionally alter personality, mood, or cognition
Unintended Neural Effects	- Unpredictable interactions with neurons/glia - Modulation of neurotransmitters/synaptic signaling - Irreversible or long-acting formulations raise stakes
Human Enhancement Debate	- Nano-drug platforms could be misused for cognitive enhancement rather than therapy
Long-Term Safety & Neurotoxicity	- Limited long-term human data - Potential for inflammation, accumulation, or neuronal damage - CNS has limited regenerative ability
Data Privacy & Neurological Information	- Smart nano-systems may collect neural/biological signals - Raises concerns about data storage, access, and future use
Oversight Mechanisms & Ethical Review	- Conventional IRBs may lack nanotech/neuroethics expertise - Need for interdisciplinary review boards - Ongoing (not just one-time) ethical evaluations required
Equity, Access & Global Justice	- Risk of expensive, patented therapies worsening healthcare disparities - Disproportionate impact on the elderly, poor, and underserved
Public Perception & Trust	- Misunderstanding could lead to fear, stigma, resistance - Need for transparent public communication and involvement
Ethical Imperatives Going Forward	- Development of tailored ethical frameworks specific to nano-brain delivery - Proactive governance to protect autonomy, dignity, and justice

4. Current Clinical Trials Status In Nanotechnology Treating Ad

The clinical trial landscape for nanomedicine in AD is emerging as a promising yet challenging frontier. As traditional drugs struggle to effectively cross the BBB and deliver therapeutic payloads to affected neural tissues, nanotechnology offers a sophisticated solution through targeted, sustained, and brain-penetrant delivery systems. Current clinical trials, though limited in number compared to preclinical studies, represent a significant step toward translating nanoformulations from bench to bedside (**Table 10.3**). These trials are mostly in early-phase (Phase I and II), focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy. Some involve the reformulation of existing Alzheimer's drugs, such as donepezil or rivastigmine, within nano-based carriers to enhance BBB permeability, while others explore novel agents delivered via nanosystems [54-55].

For instance, trials using curcumin-loaded nanoparticles or antioxidant-based nanocarriers aim to target amyloid-beta aggregation and oxidative stress, both hallmark features of Alzheimer's pathology. However, success stories remain sparse, as very few nanotherapeutics have progressed beyond Phase II trials. Several setbacks-such as nanoparticle instability, immunogenic responses, inconsistent results in human subjects, and manufacturing scalability-have stalled the advancement of otherwise promising formulations. Additionally, regulatory uncertainties pose a significant barrier to trial progress. Emerging collaborations between academic institutions, biotech firms, and public health bodies are helping to address some of these barriers by creating standardized protocols and shared databases. Ultimately, while the clinical trial landscape for nano-brain drug delivery in AD is still developing, it reflects a cautious but determined push toward overcoming the translational bottlenecks inherent in this complex therapeutic space [56].

Table 10.3: List of clinical trials current status of nanotechnology in treating AD

Study Title	Study Type	NCT Number	Status	Interventions	Sponsor	Start Date
Phase 3 Clinical Trial of Wujia Yizhi Granules	Interventional	NCT06534723	Phase 3	Drug: Wujia Yizhi granules	Sichuan Jishengtang	2024-08-20

in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)				Drug: Placebo	Pharmaceutical Co., Ltd.	
Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression	Interventional	NCT06898424	Not Applicable	Behavioral: Ketoflex 12/3 Diet	Prof. Lutfu Hanoglu, MD	2024-03-01
Interest of the Reborn® Doll as a TO in the Care of Residents With Alzheimer's Disease or a Related Disorder (PROTMA)	Interventional	NCT06396377	Not Applicable	Device: Reborn doll (Therapeutic object - OT)	University Hospital, Clermont-Ferrand	2024-09-16
Accelerated Intermittent Theta-burst Stimulation to Modify Cognitive Function and Balance in Dementia and Memory Loss	Interventional	NCT06445894	Not Applicable	Device: Active Repetitive Transcranial Magnetic Stimulation Device: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)	McMaster University	2024-06-01
Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD Registry)	Observational	NCT07058129	Observational	Procedure: Deep cervical lymphatic venous anastomosis	Beijing Tiantan Hospital	2025-07-30
Clinical Utility of Early Vs. Late Blood Biomarker Testing for Alzheimer's	Interventional	NCT06856681	Not Applicable	Diagnostic Test: PrecivityAD2 - Early Testing	C2N Diagnostics	2025-07

Disease (ADELAIDE)				Diagnostic Test: PrecivityAD2 - Delayed Testing		
Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease	Interventional	NCT06495957	Not Applicable	Other: Electroacupuncture group Other: Micro-acupuncture group	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	2024-07-20
A Genetic Study for Alzheimer Dementia: Case-control Study	Observational	NCT06330155	-----	----	MinYoung Kim, MD, PhD	2024-03-26
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type	Interventional	NCT07066826	Phase 2 Phase 3	Drug: Huperzine A Controlled-Release Tablets Drug: Donepezil hydrochloride tablets Drug: Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo	Wanbangde Pharmaceutical Group Co., LTD	2025-08-01
Clinical Evaluation of Blood-Based Assays for Rapid Detection of Aβ Pathology in Alzheimer's Disease (CLEAR AD)	Observational	NCT06889896	---	Diagnostic Test: After Blood samples collection, these samples are analyzed at a central laboratory under blinded	Anhui Provincial Hospital	2024-07-11

				conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau		
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease	Interventional	NCT06996730	Phase 2 Phase 3	Drug: Donanemab Drug: RG6289 Drug: Donanemab placebo Drug: RG6289 placebo	Banner Health	2025-12
Statins, Cholesterol and Cognitive Decline in Alzheimer's	Observational [Patient Registry]	NCT06635252	---	Drug: STA 4783	Karolinska Institutet	2025-01-01

5. Intellectual Property And Patent Landscape

The intellectual property landscape for nano-brain drug delivery is becoming increasingly significant as nanotechnology-based approaches gain traction in AD therapeutics. Patents in this field not only cover novel nanoparticles and carriers but also extend to surface modifications, targeting ligands, drug encapsulation methods, and administration techniques tailored for central nervous system (CNS) delivery [57-58]. Recent patent trends reveal a growing focus on brain-targeted nanocarriers, particularly for enhancing drug delivery across the BBB (**Table 10.4**).

A surge in filings covers lipid-based nanoparticles, polymeric micelles, dendrimers, and exosomes engineered for Alzheimer’s therapy. Many patents describe

systems that enable sustained drug release, site-specific activation, or dual functions such as imaging and treatment (theranostics). Many patents list multiple assignees, reflecting growing collaboration between academia and industry. The United States remains the global leader, with a strong infrastructure for IP protection and well-established university-industry partnerships [59]. The USPTO has granted numerous patents for nanocarrier formulations targeting neurodegenerative diseases. Europe, through the European Patent Office (EPO), maintains rigorous standards but still sees active filings, particularly from Germany, the UK, and France. China has experienced rapid growth in nanomedicine patents, driven by strong government backing and increasing domestic innovation. India's activity is growing steadily, often focusing on herbal nanoformulations or indigenous innovations adapted for brain delivery [60].

Table 10.4: List of patents (Granted/Published/Designed) in the treatment of AD

Category of Patent	Application No. / CBR / Grant No.	Title	Applicant / Inventor	Filing Date	Published / Granted / Designed Date
China (CN)	CN202410091174.7A	A PET-based auxiliary diagnosis method for early Alzheimer's disease	Zhao Jie, Lin Yuan, Wang Yuling	2024-01-23	2024-04-19
CN	CN202411369620.2A	A method and system for predicting the course of Alzheimer's disease based on coordinate attention	Hong Xin, Wang Nao, Luo Yuansen	2024-09-29	2025-01-24
CN	CN202410682577.9A	Alzheimer's disease early screening method, device, computer equipment and storage medium	Wu Peiping	2024-05-29	2024-10-01
CN	CN202410868545.8A	A method for constructing an MRI image training set and an Alzheimer's	Zhou Chao, Xu Shubo, Zheng Yinghao	2024-07-01	2024-10-18

		disease prediction model			
CN	CN202510558326.4A	Application of caffeic acid butanediamide in preparing medicines, health products or functional foods for preventing and treating Alzheimer's disease	Ma Xueqin, Sa Yuping	2025-04-29	2025-07-11
CN	CN202510041414.7A	Composition beneficial for improving brain cognition, memory and sleep and preventing and improving Alzheimer's disease	Guo Xiaopeng, Yin Lina	2025-01-10	2025-04-15
CN	CN202510013710.6A	Lactobacillus paracasei and breast milk oligosaccharide composition with synergistic effect for preventing and treating Alzheimer's disease	Fang Bing, Zhang Ming, Wang Ran, Li Yixuan	2025-01-06	2025-03-28
CN	CN202510388226.1A	Spontaneous speech-based detection system, device, storage device, and method for Alzheimer's disease	Li Jiyun, Sun Alang, Zhu Meiqing, Qian Chen, Chen Yi, Di Jingkai	2025-03-31	2025-07-04
CN	CN202510149792.7A	Alzheimer's disease blood marker joint inspection kit and manufacturing method thereof	Hu Ting, Han Xunling, Liu Xuechao, Luo Feng	2025-02-11	2025-06-06
CN	CN202510695311.2A	Application of PI3K activators in the treatment of Alzheimer's disease	Liu Qing, Zhang Xue, Wang Gaojie	2025-05-28	2025-06-27

CN	CN202510158559.5A	Method for screening biomarkers for early non-invasive Alzheimer's disease screening based on machine learning	Yang Naixue, Ma Wenqian, Wu Li	2025-02-13	2025-05-30
CN	CN202510591838.0A	Alzheimer's disease data processing method and system	Gu Bing, Tang Bo, Zhou Jian	2025-05-09	2025-06-06
CN	CN202510224057.8A	Terahertz radiation intervention and analysis methods for Alzheimer's disease model nematodes	Wang Lei, Wang Meng, He Mingxia, Zhang Xumei	2025-02-27	2025-05-27
CN	CN202510218564.0A	Application of arabinose in the preparation of drugs for treating Alzheimer's disease	Huang Yunpeng, Liu Xiaodi, Hu Jiaxin, Zheng Keke	2025-02-26	2025-05-16

In summary, while nanotechnology presents powerful opportunities for AD, a strategic and well-coordinated IP approach is essential to navigate the evolving patent landscape, ensure innovation protection, and support equitable therapeutic access.

6. Current Challenges, Limitation And Gaps In Regulatory And Ethical Consideration

The regulation and ethical governance of nano-brain drug delivery systems for Alzheimer’s disease remain fragmented and underdeveloped, despite the fast-paced advancement of nanotechnologies in neuroscience. The intersection of brain-targeting nanocarriers with human cognitive systems introduces not only technical complexities but also novel ethical and societal challenges. These challenges are particularly critical given the vulnerability of Alzheimer’s patients, the irreversible nature of CNS interactions, and the multidisciplinary nature of nanotherapeutic platforms. Although several national and regional frameworks have attempted to accommodate emerging neurotechnologies, they fall short of offering cohesive, globally applicable standards and

ethical safeguards. Three interconnected issues-lack of standardization, limited transparency and harmonization, and insufficient public trust and policy integration-constitute major gaps in the current system [61-62].

A fundamental issue lies in the lack of standardization in the regulatory assessment of nano-brain therapeutics. Nanomedicines are highly complex entities that involve diverse materials, sizes, surface coatings, and biological behaviors, particularly when designed to cross the blood-brain barrier (BBB). Despite this complexity, global regulatory bodies such as the FDA, EMA, CDSCO, and others have yet to agree on a universal framework for evaluating safety, efficacy, and quality of brain-targeted nanoformulations. Each agency has its own criteria and definitions-for example, some classify nanomedicine strictly by size (1–100 nm), while others focus on function, such as targeting ability or bio-distribution in neural tissue [63].

This inconsistency leads to varied preclinical data requirements, unclear toxicology standards, and unpredictable approval pathways. Compounding this problem, analytical techniques used for characterizing nanoparticles-such as zeta potential, particle size distribution, or surface charge-are not consistently mandated or interpreted across jurisdictions. For developers, this results in scientific ambiguity and regulatory uncertainty. From an ethical standpoint, the lack of standard guidelines makes it difficult for institutional review boards (IRBs) or ethics committees to evaluate whether a nanoformulation presents novel risks, especially when interacting with neuronal structures or cognitive functions. Without nanotechnology-specific bioethical standards, ethical review processes often default to general biomedical principles, which may be inadequate for addressing the unique risks of CNS-directed nanocarriers. Closely related to the standardization gap is the limited transparency and global harmonization of regulatory and ethical oversight**.** In most jurisdictions, regulatory decisions about nanomedicine approval or trial design are made behind closed doors, with limited public release of data or rationale [64-66]. This lack of openness makes it difficult for scientists, industry, and even other regulators to understand the benchmarks being used, undermining reproducibility and collaborative innovation.

Furthermore, while global platforms like the ICH have helped align pharmaceutical regulatory standards to some degree, no equivalent framework exists for nanomedicine-especially those targeting the brain. Consequently, a product approved in one country may face significant hurdles in another due to differing safety thresholds, ethical concerns, or procedural expectations. The absence of mutual recognition mechanisms for nano-brain therapeutics further fragments the field, forcing companies to navigate duplicate or contradictory regulatory processes across regions. Ethical oversight also lacks international coherence. IRBs and ethics committees often operate independently and interpret ethical risks differently, especially in vulnerable populations like Alzheimer's patients [67]. There is currently no global ethical registry or communication platform to facilitate the sharing of nano-bioethical concerns, best practices, or post-trial monitoring frameworks. Moreover, most regions do not require publication of ethics board decisions or justifications, thereby reducing transparency and limiting accountability. This opacity ultimately weakens the protection of trial participants and impedes cross-border harmonization [68].

The third major gap concerns the failure to meaningfully address public trust and integrate nanomedicine policy into broader social, ethical, and healthcare systems**.** Nano-brain therapeutics, due to their connection with cognition, memory, and identity, pose significant ethical dilemmas. However, the public discussion surrounding these matters is limited, and there are few avenues for incorporating patient perspectives or societal feedback into the development of research or policy priorities. Informed consent is particularly challenging in Alzheimer's clinical trials, where patients may not possess the cognitive ability to fully grasp the risks, long-term consequences, or the innovative nature of the technology. The consent process often depends on legal guardians or proxies, yet there is a lack of guidance on how to ensure that decisions reflect patient values when direct communication is no longer feasible [69-70]. Furthermore, the intricate technical nature of nanomedicine-spanning from particle dynamics to bio-distribution kinetics-complicates the explanation of these interventions to non-expert audiences in a manner that promotes genuine understanding and informed decision-making. Consequently, trust in the safety and intent of these technologies may be tenuous, particularly if adverse events arise or if media coverage emphasizes concerns

about brain manipulation or uncertain long-term effects. Despite their critical role in fostering societal acceptance, public engagement strategies such as community dialogues, stakeholder workshops, or educational initiatives are seldom put into practice.

Policy integration is also lacking [71]. In many countries, innovation policies promoting nanotechnology development are disconnected from national healthcare strategies, ethical governance systems, or Alzheimer's treatment roadmaps. This creates a mismatch between scientific progress and institutional preparedness. For example, public funding may prioritize patent-intensive nanotech startups without ensuring that resulting products are affordable or accessible through public health channels. Ethical frameworks, meanwhile, often lag behind, failing to anticipate future concerns such as data privacy from nano-sensors, cognitive enhancement debates, or the regulation of brain-machine interface systems. Interdisciplinary policymaking that bridges science, ethics, economics, and healthcare is needed, but it remains rare. Most governments treat nanomedicine as a siloed domain, limiting opportunities for holistic governance [72-73].

In conclusion, while nanotechnology holds great promise for the diagnosis and treatment of Alzheimer's disease through targeted brain drug delivery, the supporting regulatory and ethical infrastructure remains inadequate in several critical dimensions. A lack of standardization undermines scientific rigor and consistency in safety assessments; limited transparency and global harmonization reduce trust and create inefficiencies; and insufficient public engagement and policy alignment increase the risk of ethical blind spots, societal backlash, or inequitable access [74]. To address these challenges, a globally coordinated, multidisciplinary effort is essential. This would involve harmonizing regulatory definitions and evaluation tools, creating shared ethical oversight mechanisms, and embedding public engagement into nanomedicine policy. Only by strengthening these foundational systems can the field responsibly translate nano-brain innovations from research labs into real-world impact for patients with Alzheimer's and related neurological disorders [75].

7. Future Directions And Policy Recommendations

The progress of nano-brain drug delivery systems presents significant potential for the treatment of CNS disorders, offering greater precision and minimizing systemic

toxicity. Nevertheless, to effectively transition these advancements from research to clinical application, future efforts must focus on the integration of regulatory harmonization, ethical oversight, and translational research. Regulatory agencies like the FDA, EMA, and CDSCO need to create nano-specific guidelines designed for brain-targeted therapies, ensuring that nanocarriers are evaluated not only for their physicochemical properties but also for their long-term biocompatibility and neurotoxicity [76-77]. Furthermore, strong ethical frameworks are essential to protect patient rights during clinical trials, particularly given the complexities associated with brain-targeting interventions and their potential irreversible consequences. More transparency in reporting nanomedicine trials and the inclusion of diverse populations should be encouraged [78].

Furthermore, policies must foster public–private collaborations to overcome high R&D costs and streamline the patenting process, which often lacks clarity in nanotechnology-based inventions. Promoting open-access databases for patents and clinical trials will facilitate innovation and prevent redundancy. Policymakers should also incentivize the development of "green" nanotechnologies to align with sustainability goals. Overall, a multidisciplinary and globally coordinated policy framework is essential to unlock the full potential of nano-brain drug delivery systems while ensuring safety, efficacy, and ethical compliance [78-80].

Conclusion

The delivery of drugs via nano-brain technology is emerging as a revolutionary method for treating neurodegenerative diseases like Alzheimer's. However, the clinical, regulatory, ethical, and intellectual property aspects are still evolving. Regulatory bodies such as the FDA, EMA, and CDSCO have recognized the distinct challenges posed by nanomedicine, yet there is still a lack of harmonized, nano-specific regulatory frameworks, especially for central nervous system applications. Ethical issues continue to be a concern, particularly regarding autonomy, informed consent, and the long-term effects on neural health in populations with cognitive impairments. While initial clinical trials indicate potential for improved drug delivery across the blood-brain barrier, the transition to late-stage applications is hindered by methodological and infrastructural challenges. Patent activity is increasing globally, but overlapping claims, difficulties in

enforcement, and disparities in access are ongoing obstacles to advancement. To unlock the full potential of nano-brain therapies, a comprehensive framework is necessary. This framework should integrate ethical foresight, globally standardized regulations, active collaboration among stakeholders, and models for equitable access. Such coordinated initiatives are crucial for translating nanotechnology into safe, effective, and accessible therapies aimed at the brain, ultimately enhancing patient outcomes on a global scale.

Acknowledgement

The authors would like to express their sincere gratitude to *Deep Science Publisher* and the editorial team of this book for their invaluable support in the final publication process and for providing the opportunity to contribute to this esteemed volume.

Conflicts of Interest

The authors declare that there are no conflicts of interest related to this work.

Funding Source

No funding was received for the preparation of this book chapter.

Author Contribution

All authors have contributed equally to the conception, preparation, and completion of this book chapter.

References

1. U.S. FDA. Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry. 2022 Apr 20.
2. U.S. FDA. Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry (PDF). 2022.
3. Federal Register. Drug Products… that Contain Nanomaterials; Guidance for Industry. 2022 Apr 22.
4. Đorđević S, González MM, Conejos-Sánchez I, Caro C, Pozo D, Ortega-Vinuesa JL, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. *Acta Biomater.* 2021;119:21–46.
5. Halwani AA. Development of pharmaceutical nanomedicines: Challenges and opportunities. *Pharmaceutics.* 2022;14(2):253.
6. Pal R, Pandey P, Rai B, Koli M, Chakrabarti M, Thakur P, Rizwan M, Saxena A. Chitosan: as highly potential biopolymer obtainable in several advance drug delivery systems including biomedical applications. Environmental science. 2023;3(4).
7. EMA. Scientific publications page (nanomedicine reflections and related guidance). 2025.

8. DBT–ICMR–CDSCO (India). Guidelines for Evaluation of Nanopharmaceuticals in India. 2019.
9. CDSCO (India). Revised Guidance for Industry aligning with New Drugs & Clinical Trials Rules 2019. 2019.
10. Thomas J, Nair A, Joseph A. Recent approaches in nanotoxicity assessment for drug delivery applications. *Mater Today Adv.* 2025;18:100412.
11. Chen Q, Zhang X, Li J, Zeng H, Wang X. Systemic treatments for breast cancer brain metastasis: opportunities and challenges. *Front Oncol.* 2023;12:1086821.
12. Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, et al. ANG1005, a brain-penetrating peptide–drug conjugate, shows activity in brain metastases. *Clin Cancer Res.* 2020;26(12):2789–99.
13. Dmello C, Allen C, Dunn IF, Batchelor TT, Dietrich J. Phase II trial of blood–brain barrier permeable peptide–paclitaxel conjugate for high-grade glioma. *Neurooncol Adv.* 2024;6(1):vdad179.
14. Rakhi Mishra, Rahul Pal, Zuber Khan, Subhashree Sahoo, Himmat Singh Chawra, Dinesh Kumar, Solid Lipid Nanoparticles (SLNPs): A State-of-the-Art Formulation Strategy and their Applications against Tuberculosis (TB) and Analgesic Effects, Nanoscience & Nanotechnology-Asia; Volume 15, Issue 3, Year 2025, e22106812379362. DOI: 10.2174/0122106812379362250602075954
15. Brandsma D, van den Bent M, van Herpen C, et al. 2B3-101 (glutathione-PEGylated liposomal doxorubicin) in patients with solid tumors and brain mets or recurrent glioma (Phase I/IIa). *Ann Oncol.* 2014;25(Suppl 4):iv159.
16. Kerklaan BM, et al. NT-23: Phase 1/2A study of glutathione-PEGylated liposomal doxorubicin (2B3-101). *Neuro Oncol.* 2014;16(Suppl 5):v167.
17. Jourdain MA, et al. Recent advances in liposomes and peptide-based BBB strategies in GBM. *J Control Release.* 2024;364:469–88.
18. Raju R, et al. Liposomes for the treatment of brain cancer—A review. *Pharmaceuticals.* 2023;16(8):1056.
19. ClinicalTrials.gov. NCT03613181: ANG1005 in leptomeningeal disease from breast cancer (Phase 3).
20. Patsnap Synapse. Paclitaxel trevatide (ANG1005): targets, trials, patents (summary). 2022–2025.
21. ClinicalTrials.gov. NCT03739905: ExAblate BBB opening for Alzheimer's disease (Phase IIa).
22. ClinicalTrials.gov. NCT04118764: Non-invasive BBB opening in Alzheimer's disease.
23. ClinicalTrials.gov. NCT03119961: Blood–brain barrier opening in Alzheimer's disease.
24. ClinicalTrials.gov. NCT03806478: Intranasal APH-1105 for mild–moderate Alzheimer's (Phase 2).
25. Maussang D, et al. Glutathione conjugation dose-dependently increases brain exposure of liposomal drugs. *Nanomedicine.* 2016;11(8):XXX–XXX.
26. Gaillard PJ, et al. Development of glutathione-PEGylated liposomal doxorubicin (2B3-101) for brain tumors. *Cancer Res.* 2012;72(8 Suppl):Abstract 5687.
27. US Patent 8,710,013 B2. Pharmaceutical compositions of paclitaxel-peptide conjugates (ANG1005). 2014.
28. WO2009/127072 A1. Pharmaceutical compositions of paclitaxel conjugates (Angiopep-2). 2009.
29. US 9,365,634 B2. Angiopep-2 conjugates and uses for BBB transport. 2016.
30. Biospace. AngioChem granted first US patent covering Angiopep-2 BBB transport. 2009.
31. WO2022/074181 A1. Nanocarrier formulations for inhalation linked to glutathione receptor ligands. 2022.

32. OECD. Recommendation on Responsible Innovation in Neurotechnology (OECD/LEGAL/0457). 2019 (toolkits updated 2024).
33. OECD. Neurotechnology Toolkit: Implementing the Recommendation. 2024.
34. UNESCO. Ethics of Neurotechnology—IBC report and draft Recommendation process (2024–2025).
35. Ramanathan M. The UNESCO draft Recommendations on ethics of neurotechnology: a commentary. *Indian J Med Ethics.* 2025;10(2):89–91.
36. Nuffield Council on Bioethics. Neurotechnology literature review. 2024.
37. O'Shaughnessy MR, et al. Neuroethics guidance documents: principles and analysis. *AJOB Neurosci.* 2023;14(4):226–39.
38. Gupta U, Kosey S, Pal R. Advancements in Nanotechnology-Based Targeted Drug Delivery Systems for Glioblastoma Chemotherapy: A Comprehensive Review. Journal of Drug Delivery Science and Technology. 2025 Jun 13:107181.
39. Daly TP. Ethical issues around treatment-induced ARIA and informed consent in Alzheimer's therapy. *JAMA Neurol.* 2024.
40. Korecky K, et al. Unresolved ethical questions of mHealth apps for dementia prevention. *npj Digit Med.* 2025;8.
41. Dino FR, et al. Ethics in digital phenotyping: informed consent complexities in Alzheimer's. *npj Digit Med.* 2025;8.
42. Tressa A, Singh A, Pal R, Kumar N. Novel Nanocarriers Microencapsulation: Current, Patents and Clinical Trials Comprehensive Review. Journal of Drug Delivery & Therapeutics. 2025 Apr 1;15(4).
43. Pal R, Pandey P, Chawra HS, Singh RP. Niosomal as Potential Vesicular Drug Nano-carriers for the Treatment of Tuberculosis (TB). Nanoscience & Nanotechnology-Asia. 2025 Feb;15(1):E22106812323829.
44. Mittmann N, et al. Health technology assessment and reimbursement of advanced therapeutics in oncology: implications for nanomedicine. *Curr Oncol.* 2024;31.
45. Garden H, Pfotenhauer S. Responsible innovation in neurotechnology enterprises. OECD Working Paper. 2019.
46. Illes J, et al. Principles and priorities for responsible innovation in neurotechnology for Canada. *Can J Neurol Sci.* 2025;52(3):e1–e8.
47. European Brain Council. European Charter for the Responsible Development of Neurotechnologies. 2025.
48. UNESCO. Towards an International Instrument: Draft Recommendation on Ethics of Neurotechnology (intergovernmental phase updates). 2024–2025.
49. Frontiers/Reviews. Blood–brain barrier conquest in glioblastoma: clinical progress and barriers. *Signal Transduct Target Ther.* 2024;9.
50. Xin H, et al. Brain targeting mechanism of Angiopep-conjugated nanoparticles. *J Control Release.* 2012;163(2):240–50.
51. Wilcox JA, et al. Leptomeningeal metastases: new opportunities in drug delivery and trials. *Clin Neurol Neurosurg.* 2023;225:107625.
52. Patsnap Synapse. 2B3-101 (2X-111) development history and IP landscape. 2017–2025.
53. 2-BBB Medicines. 2B3-101 product overview (G-Technology platform). Company resource.
54. BioWorld. 2X Oncology obtains IND for 2X-111 from 2-BBB Medicines. 2017.
55. Jourdain MA, et al. (peptide-decorated liposomes—clinical lessons). *J Control Release.* 2024;364:469–88.
56. Frontiers in Oncology (Chen Q, 2023) — ANG1005 CNS outcomes subset analysis. *Front Oncol.* 2023;12:1086821.
57. Federal/India. DBT–ICMR–CDSCO Nanopharma Guidelines (AIIMS mirror). 2018/2019.
58. RAPS. FDA finalizes guidance for nanomaterials in drugs and biologics. 2022 Apr 25.

59. Pal R, Pandey P, Chawra HS, Khan Z. Nano Drug Delivery Carriers (Nanocarriers): A Promising Targeted Strategy in Tuberculosis and Pain Treatment. Pharmaceutical Nanotechnology. 2025 Mar 7.
60. ClinicalTrials.gov. ExAblate BBB disruption device study in brain tumors (Type 2.0, 220 kHz). NCT03671889.
61. ClinicalTrials.gov. ANG1005 trial entries—study records and outcomes (aggregate). Accessed 2024–2025.
62. OECD. Responsible innovation—topic hub (neurotechnology section). 2024–2025.
63. UNESCO Chair (AUP). Updates on UNESCO Ethics of Neurotechnology process. 2024.
64. Bionics Gamechangers. UNESCO drafts Recommendations on neurotech ethics (news explainer). 2024.
65. Cambridge/OU Press. The OECD approach to responsible innovation in neurotechnology. 2024.
66. Mdpi/Int J Mol Sci. Nanomedicine strategies addressing AD pathology and BBB. 2023;24(18):14044.
67. *Brain/BMJ* (Daly TP). Informing consent for Alzheimer's monoclonal antibodies—ethics. 2023–2024.
68. *AJOB Neurosci.* O'Shaughnessy MR, et al. Neuroethics guidance mapping. 2023;14(4):226–39.
69. *Signal Transduct Target Ther.* Duan M, et al. BBB conquest in GBM (clinical and translational status). 2024;9:XX–XX.
70. *Clin Cancer Res.* Kumthekar P, et al. ANG1005 data (PDF preprint). 2020;26(12):2789–99.
71. *J Control Release.* Jourdain MA, et al. Peptide-decorated liposomes (clinical lessons). 2024;364:469–88.
72. Google Patents. WO2022235514 A1: Liposome delivery of psychedelics (BBB-relevant nano-IP). 2022.
73. Google Patents. WO2022074181 A1: LNPs for inhalation with glutathione receptor ligands. 2022.
74. Google Patents. US8710013 B2 and family: Angiopep-2 paclitaxel conjugates. 2014.
75. Google Patents. WO2009/127072 A1 and family: Angiopep-2 conjugates enabling BBB transport. 2009.
76. *Ann Oncol.* Brandsma D, et al. 2B3-101 Phase I/IIa abstract. 2014;25(Suppl 4):iv159.
77. *Neuro Oncol.* Kerklaan BM, et al. NT-23 abstract: 2B3-101 clinical data. 2014;16(Suppl 5):v167.
78. *PLoS One.* Gaillard PJ, et al. 2B3-101 brain delivery and efficacy. 2014;9(1):e82331.
79. *Front Oncol.* Chen Q, et al. BCBM systemic therapy with BBB-penetrant agents incl. ANG1005. 2023;12:1086821.
80. EMA Publications portal—nanomedicine reflections and CNS-relevant publications (index). 2025.